comprehensive -WSS

comprehensive

author：explore 2025-09-05 09:20:16 - browse：7

RHONA WISE/AFP via Getty Images

WASHINGTON — Drugmakers are doing everything to tap the bottomless well of demand for new obesity drugs, and they might get some government help. The agency that regulates Obamacare insurance is considering a technical change that would require insurers to cover obesity drugs in a market of more than 20 million Americans.

Weight loss drugs are a blessing for patients, a boon for drugmakers, and a potentially huge expense for insurers and taxpayers. Insurers have been slow to cover the drugs, called GLP-1 agonists, and without insurance, it costs upward of $16,000 annually for a drug that must be taken indefinitely.

There is a lot of demand for the drugs, but there are barriers to coverage. Medicare by law is prohibited from paying for obesity drugs. State Medicaid programs don’t have to cover them, so most don’t.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Europe sees delivery challenges ahead on Alzheimer's therapies

WSS

The new HIV moral panic

Michigan AG announces felony charges against 'fake electors' in 2020 election plot

Care demand spikes challenge UnitedHealth’s provider arm

Federal judge rules Oregon’s tough new gun law is constitutional

Eli Lilly to acquire Versanis in heated race for weight loss drugs

American woman kidnapped in Mexico freed after 8 months in captivity: FBI

focus

comprehensive

explore

Bright Health sells Medicare Advantage business to Molina

Global childhood vaccinations edge closer to pre

In Memoriam: Notable people who died in 2023

Why police arrested suspected Gilgo Beach killer away from his house

What does generative AI mean for health care? We asked experts

Obesity drugs seen as possible treatment for liver disease MASH

Medicare details structure of new drug price negotiation program

In utero gene editing: an explainer

After affirmative action ruling, medical educators look to 'holistic review'

Global childhood vaccinations edge closer to pre

focus

Can CDC director Mandy Cohen drive consensus in Washington?

Involuntary treatment for addiction doesn't work

Mike Pence clashes with Tucker Carlson in Iowa

Alabama hospital puts IVF treatments on hold

A new nitrogen execution bill also undermines medical licensing

The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio

hotspot

explore

focus

leisure time